erlotinib has been researched along with Bladder Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cacaccio, J; Chandra, D; Cheruku, RR; Durrani, FA; El-Khouly, ME; Fukuzumi, S; Guru, K; Kumar, R; Marko, A; Missert, JR; Pandey, RK; Sajjad, M; Tabaczynski, WA; Watson, R; Yao, R | 1 |
1 other study(ies) available for erlotinib and Bladder Cancer
| Article | Year |
|---|---|
Epidermal Growth Factor Receptor-Targeted Multifunctional Photosensitizers for Bladder Cancer Imaging and Photodynamic Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, SCID; Photochemotherapy; Photosensitizing Agents; Positron-Emission Tomography; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |